Related Experiment Videos
Early phase II trial of human rotavirus vaccine candidate RV3
Graeme L Barnes1, Jennifer S Lund, Susan V Mitchell
1Murdoch Children's Research Institute, Royal Children's Hospital, Parkville, Melbourne, Vic. 3052, Australia. bernesg@cryptic.rch.unimelb.edu.au
Insights
The rotavirus vaccine candidate RV3 showed 54% efficacy against rotavirus disease in infants who mounted an immune response. Further trials are needed to enhance the immunogenicity of this promising human rotavirus vaccine.
Area of Science:
- Virology
- Vaccinology
- Pediatric Infectious Diseases
Background:
- Rotavirus is a leading cause of severe diarrheal disease in infants globally.
- Development of safe and effective rotavirus vaccines is a public health priority.
- The naturally attenuated human neonatal rotavirus strain RV3 has shown potential as a vaccine candidate.
Purpose of the Study:
- To evaluate the safety and efficacy of the rotavirus vaccine candidate RV3 in a Phase II clinical trial.
- To assess the immunogenicity and protective efficacy of RV3 against rotavirus gastroenteritis.
Main Methods:
- A randomized, double-blind, placebo-controlled Phase II trial was conducted.
- Infants received three doses of RV3 vaccine (6.5 x 10^5 fcfu) or placebo at 3, 5, and 7 months of age.
- Immune response and protection against rotavirus disease were monitored.
Main Results:
- The RV3 vaccine was administered safely, with limited replication suggested by lack of virus excretion.
- An immune response was observed in 46% of vaccinated infants.
- Partial protection (54% efficacy) against rotavirus disease was observed in infants who developed an immune response, indicating heterotypic protection.
Conclusions:
- The rotavirus vaccine candidate RV3 demonstrated partial protective efficacy, supporting its potential.
- Strategies to improve the immunogenicity of RV3 are necessary for broader application.
- Further clinical trials are warranted to optimize this human rotavirus vaccine.
Abstract:
A naturally attenuated, human neonatal strain, rotavirus vaccine candidate RV3, was tested in a limited phase II randomized double-blind controlled trial. Doses of 1 ml, containing placebo or 6.5 x 10(5) fluorescent cell forming units (fcfu) of virus in AGMK cells, were given at 3, 5 and 7 months of age. Limited replication in the small intestine is implied by the lack of virus excretion, and by the occurrence of an immune response in only 46% of the infants. However, those who developed an immune response were partially protected against rotavirus disease during the subsequent winter epidemic (protective efficacy 54%), supporting observations of protection induced by natural infection by this strain. Protection appeared to be heterotypic. Further trials are warranted, employing strategies to increase immunogenicity of this human rotavirus candidate vaccine.